: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999, 1:461–466.PubMedSelleckchem Torin 2 CrossRef 29. Hiromi K, Minoru I, et al.: Enhancement of Cisplatin Sensitivity in Squamous Cell Carcinoma of the Head and Neck Transfected With a Survivin Antisense

Gene. Archoto head neck surg 2006, 132:682–685.CrossRef 30. Kuwahara D: Caspase-9 regulates cisplatin-induced apoptosis in human head and https://www.selleckchem.com/products/pifithrin-alpha.html neck squamous cell carcinoma cells. Cancer Letters 2000, 148:65–71.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions DDY carried out cell transfection, animal experiment, histologic analysis and drafted the manuscript. CTW participated in animal experiment, histologic analysis and selleck chemicals llc helped to draft the manuscript. HSS and ZYL contributed to animal experiment. LP, FL, QZY and YW participated in plasmid DNA preparation. XC carried out Liposome preparation. YQW supervised experimental work and revised the manuscript. All authors read and

approved the final manuscript.”
“Background The therapeutic approach based on induced cell differentiation of transformed cells into mature phenotypes is one of the most promising strategies in recent anti-neoplastic treatment. Retinoids represent the most frequently used group of differentiation inducers, both in leukemias and in some types of solid tumors [1–6]. However, evidence of potential toxicity and intrinsic or acquired resistance substantially limits the use of retinoids in clinical protocols. Special attention has thus been paid to the combined treatment with retinoids and other

compounds that are able to enhance or modulate the differentiation effect of retinoids. For example, all-trans retinoic acid (ATRA)-induced cell differentiation in the HL-60 leukemia cell line can be enhanced either by combined treatment with bile acids [7, 8] or with inhibitors of the arachidonic acid degradation pathway, especially of lipoxygenases (LOX) and cyclooxygenases (COX) [9–11]. In neuroblastomas, Ergoloid which are the most common extracranial malignant solid tumors of childhood, differentiation therapy with retinoids is of special interest. Because neuroblastomas are classified as embryonal tumors arising from immature cells of the neural crest, the induced differentiation of neuroblastoma cells has become a part of therapeutic protocols [12–16]. In our previous work, we investigated possible ways of modulating the ATRA-induced differentiation of two neuroblastoma cell lines, SK-N-BE(2) and SH-SY5Y, with LOX/COX inhibitors. We used caffeic acid (CA) as an inhibitor of 5-LOX and celecoxib (CX) as an inhibitor of COX-2. Our results clearly confirmed the power of CA to enhance the differentiation potential of ATRA, especially in the SK-N-BE(2) cells, whereas combined treatment with CX led predominantly to the cytotoxic effect [17].